Please ensure Javascript is enabled for purposes of website accessibility

Why Antares Pharma Is Crashing 12.3% Today

By Todd Campbell – May 5, 2020 at 12:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

First-quarter financial results failed to spark investors' animal spirits.

What happened

After the company reported mixed first-quarter financial results that were better than expected on the top line and worse than expected on the bottom line, shares in Antares Pharma (ATRS) had tumbled 12.3% at 12 p.m. EST on Tuesday.

So what

The healthcare company delivered robust revenue growth in Q1 because of Xyosted, a long-lasting testosterone drug, and Teva Pharmaceutical Industries' (TEVA 3.20%) generic version of Mylan's EpiPen, which uses Antares technology. Sales were $33.1 million, eclipsing industry watchers' estimates by $2.56 million and up 42.1% from the same quarter last year.

A chart drawn on a chalkboard showing a stock price peaking and then falling.

Image source: Getty Images.

However, Antares' net loss of $0.01 per share in the quarter missed estimates by $0.01, which offset optimism despite being an improvement from a loss of $0.03 per share last year. 

Also worrisome was that management removed full-year revenue guidance, citing lower new patient starts because of COVID-19 restrictions: "At this time, while we have seen a softening in new patient starts for our products, it is difficult to predict the full financial impact on our business given the current economic slowdown and uncertainty surrounding the duration of the pandemic. However, we believe the Company is in a strong financial position, allowing us to navigate through these unprecedented times while continuing to execute on our key strategic objectives supporting long-term growth," said Robert F. Apple, president and CEO.

Now what

The bigger-than-expected loss and pulled guidance aren't good news, but there are reasons for optimism.

An alternative to messy gels requiring daily application, Xyosted is taken weekly via an auto-injector. Total prescriptions grew 18% sequentially in Q1, resulting in sales of $9 million. 

Additionally, sales of Teva's generic Epipen grew 13% sequentially on a 7% increase in market share, and as a result Antares partnership revenue improved 7.4% to $14.5 million last quarter.

Overall, COVID-19 creates uncertainty, but risk-tolerant investors might want to buy this weakness. Management was targeting sales of $135 to $155 million this year before removing guidance, so if sheltering in place eases and doctor visits normalize, the company's current $545 million market cap may undervalue the company's long-term opportunity.

 

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Antares Pharma, Inc. Stock Quote
Antares Pharma, Inc.
ATRS
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$8.07 (3.20%) $0.25
Viatris Inc. Stock Quote
Viatris Inc.
MYL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.